Xeris Biopharma Holdings (XERS) Other Accumulated Expenses (2020 - 2026)

Xeris Biopharma Holdings (XERS) has 7 years of Other Accumulated Expenses data on file, last reported at $4.4 million in Q1 2026.

• Quarterly Other Accumulated Expenses rose 2690.38% year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 million (up 2690.38% YoY) and the FY2025 annual result came in at $4.9 million, up 348.94% from the prior year.
• Other Accumulated Expenses retreated to $4.4 million in Q1 2026, from $4.9 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $4.9 million in Q4 2025 to a low of $156000.0 in Q1 2025.
• A 5-year average of $1.7 million and a median of $1.1 million in 2023 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2025 — Other Accumulated Expenses slumped 80.52% — and 2026, when it soared 2690.38%.
• Tracing XERS's Other Accumulated Expenses over 5 years: stood at $2.7 million in 2022, then sank by 56.09% to $1.2 million in 2023, then declined by 6.68% to $1.1 million in 2024, then jumped by 348.94% to $4.9 million in 2025, then fell by 10.96% to $4.4 million in 2026.
• The last three Other Accumulated Expenses figures came in at $4.4 million (Q1 2026), $4.9 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.